[go: up one dir, main page]

Mihm, 2015 - Google Patents

Activation of type I and type III interferons in chronic hepatitis C

Mihm, 2015

View PDF
Document ID
11361151597211098997
Author
Mihm S
Publication year
Publication venue
Journal of Innate Immunity

External Links

Snippet

Infection with hepatitis C virus (HCV) results in chronic and progressive liver disease. Persistency rates add up to 85%. Despite recognition of the virus by the human host in peripheral blood and in the liver, immune response appears to be ineffective in clearing …
Continue reading at pmc.ncbi.nlm.nih.gov (PDF) (other versions)

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriphage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/706—Specific hybridization probes for hepatitis
    • C12Q1/707—Specific hybridization probes for hepatitis non-A, non-B Hepatitis, excluding hepatitis D
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Hybridisation probes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G01N33/576—Immunoassay; Biospecific binding assay for hepatitis
    • G01N33/5767—Immunoassay; Biospecific binding assay for hepatitis non-A, non-B hepatitis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells

Similar Documents

Publication Publication Date Title
Mihm Activation of type I and type III interferons in chronic hepatitis C
Jiang et al. Identification of three interferon-inducible cellular enzymes that inhibit the replication of hepatitis C virus
Mangia et al. An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response
Matsuura et al. Role of IL28B for chronic hepatitis C treatment toward personalized medicine
Lange et al. IL28B single nucleotide polymorphisms in the treatment of hepatitis C
Kelly et al. Interferon lambdas: the next cytokine storm
Bigger et al. DNA microarray analysis of chimpanzee liver during acute resolving hepatitis C virus infection
Jilg et al. Kinetic differences in the induction of interferon stimulated genes by interferon‐α and interleukin 28B are altered by infection with hepatitis C virus
Frese et al. Hepatitis C virus RNA replication is resistant to tumour necrosis factor-α
Yang et al. Hepatitis C virus and antiviral innate immunity: who wins at tug-of-war?
Fischer et al. Sex-specific effects of TLR9 promoter variants on spontaneous clearance of HCV infection
Laidlaw et al. Interferon lambda: opportunities, risks, and uncertainties in the fight against HCV
Biasin et al. Endoplasmic reticulum aminopeptidase 2 haplotypes play a role in modulating susceptibility to HIV infection
Wei et al. Single nucleotide polymorphisms of toll-like receptor 7 and toll-like receptor 9 in hepatitis C virus infection patients from central China
Ho et al. Genotype 3 is the predominant hepatitis C genotype in a multi-ethnic Asian population in Malaysia
Mizokami Discovery of critical host factor, IL‐28B, associated with response to hepatitis C virus treatment
Bellanti et al. The impact of interferon lambda 3 gene polymorphism on natural course and treatment of hepatitis C
Wyles et al. Synergy of small molecular inhibitors of hepatitis C virus replication directed at multiple viral targets
Torres‐Puente et al. Genetic variability in hepatitis C virus and its role in antiviral treatment response
Tanaka et al. λ‐Interferons and the single nucleotide polymorphisms: A milestone to tailor‐made therapy for chronic hepatitis C
Imran et al. Correlation of OAS1 gene polymorphism at exon 7 splice accepter site with interferon-based therapy of HCV infection in Pakistan
Broering et al. Long‐term stimulation of T oll‐like receptor 3 in primary human hepatocytes leads to sensitization for antiviral responses induced by poly I: C treatment
Angulo et al. Genetic variations in host IL 28 B links to the detection of peripheral blood mononuclear cells–associated hepatitis C virus RNA in chronically infected patients
Nozawa et al. Genetic polymorphism in IFNL4 and response to pegylated interferon‐α and ribavirin in Japanese chronic hepatitis C patients
Vinuesa et al. The impact of virus population diversity on the dynamics of cytomegalovirus DNAemia in allogeneic stem cell transplant recipients